These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 29739227

  • 1. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
    Duan W, Ou X, Wang X, Wang Y, Zhao X, Wang Q, Wu X, Zhang W, Ma H, You H, Jia J.
    Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS, Khanna A, Walker LJ, Wong LL, Dyson JK, Jones DEJ.
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
    Ding D, Guo G, Liu Y, Zheng L, Jia G, Deng J, Sun R, Wang X, Guo C, Shang Y, Han Y.
    Hepatol Commun; 2022 Dec; 6(12):3487-3495. PubMed ID: 36213941
    [Abstract] [Full Text] [Related]

  • 4. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
    Ding D, Ren P, Guo G, Liu Y, Yang C, Zheng L, Jia G, Deng J, Sun R, Wang X, Zhou X, Shang Y, Han Y.
    Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
    [Abstract] [Full Text] [Related]

  • 5. Additional fibrate treatment in UDCA-refractory PBC patients.
    Chung SW, Lee JH, Kim MA, Leem G, Kim SW, Chang Y, Lee HY, Yoon JS, Park JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Yoon JH.
    Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
    [Abstract] [Full Text] [Related]

  • 6. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
    Cheung AC, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield GM, Janssen HL, Feld JJ.
    Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.
    Wang L, Sun K, Tian A, Liu Y, Zhang M, Zhou X, Han Y.
    Minerva Med; 2022 Dec; 113(6):974-982. PubMed ID: 33949176
    [Abstract] [Full Text] [Related]

  • 9. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
    Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Horiguchi N, Kakizaki S, Kusano M, Yamada M.
    Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
    Wunsch E, Raszeja-Wyszomirska J, Barbier O, Milkiewicz M, Krawczyk M, Milkiewicz P.
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH, Lindor KD.
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [Abstract] [Full Text] [Related]

  • 14. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
    Reig A, Sesé P, Parés A.
    Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
    Levy C, Peter JA, Nelson DR, Keach J, Petz J, Cabrera R, Clark V, Firpi RJ, Morelli G, Soldevila-Pico C, Lindor K.
    Aliment Pharmacol Ther; 2011 Jan; 33(2):235-42. PubMed ID: 21083674
    [Abstract] [Full Text] [Related]

  • 19. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD.
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.